Evidence map›Paper›PMID 40540429›Full record

ArticleJournal of the American Society of Nephrology : JASN2025

Biomarkers of Kidney Failure and All-Cause Mortality in CKD.

Anthony Onoja, Thomas McDonnell, Isabelle Annessi, Rosamonde E Banks, Marianne Bergin, Paul Cockwell, Rodolphe Dusaulcy, Simon D S Fraser, Tim Johnson, Philip A Kalra and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Sex-Associated Biomarker Differences in CKD Progression and Mortality.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  5. Article
  6. Review
  7. Novel Biomarkers in CKD.Journal of the American Society of Nephrology : JASN · 2026
    Article
  8. Authors' Reply: Novel Biomarkers in CKD.Journal of the American Society of Nephrology : JASN · 2026
    Article
  9. Article
  10. Biomarkers in CKD: What Does the Future Hold?Journal of the American Society of Nephrology : JASN · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Anthony OnojaFaculty of Health and Medical Sciences, School of Health Sciences, University of Surrey, Guildford, United Kingdom.ORCID 0000-0002-1429-0032
Thomas McDonnellDonal O'Donoghue Renal Research Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.ORCID 0000-0002-2898-4457
Isabelle AnnessiDivision of Laboratory Medicine, Diagnostic Department, Faculty of Medicine, Geneva University Hospitals, Genève, Switzerland.
Rosamonde E BanksSchool of Medicine, Leeds Institute of Medical Research, St James's University Hospital, Leeds, United Kingdom.ORCID 0000-0002-0042-8715
Marianne BerginInflammatory Rheumatology FA, UCB Biopharma UK, Slough, United Kingdom.
Paul CockwellDepartment of Renal Medicine, Queen Elizabeth Hospital, Institute of Inflammation and Ageing, University Hospitals of Birmingham, Birmingham, United Kingdom.ORCID 0000-0003-1975-266
Rodolphe DusaulcyDivision of Laboratory Medicine, Diagnostic Department, Faculty of Medicine, Geneva University Hospitals, Genève, Switzerland.
Simon D S FraserFaculty of Medicine, School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-4172-4406
Tim JohnsonExperimental Renal Medicine, Human Metabolism and Oncology, The Medical School, University of Sheffield, Sheffield, United Kingdom.ORCID 0000-0003-2238-3463
Philip A KalraDonal O'Donoghue Renal Research Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.ORCID 0000-0001-7652-1572
Barbara LemaîtreDivision of Laboratory Medicine, Diagnostic Department, Faculty of Medicine, Geneva University Hospitals, Genève, Switzerland.
Moin SaleemBristol Renal and Children's Renal Unit, Bristol Medical School, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-9808-4518
Philipp SkroblinEvotec International GmbH, Göttingen, Germany.
Magnus SoderbergPathology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-0946-5202
Maarten W TaalDepartment of Renal Medicine, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom.ORCID 0000-0002-9065-212
Robert J UnwinAstraZeneca Biopharmaceuticals, Cambridge Biomedical Campus, Cambridge, United Kingdom.ORCID 0000-0001-7839-6031
Nicolas VuilleumierDivision of Laboratory Medicine, Diagnostic Department, Faculty of Medicine, Geneva University Hospitals, Genève, Switzerland.
David C WheelerDepartment of Renal Medicine, University College London, London, United Kingdom.ORCID 0000-0003-0745-3478
Nophar GeifmanFaculty of Health and Medical Sciences, School of Health Sciences, University of Surrey, Guildford, United Kingdom.ORCID 0000-0003-2956-6676

Funding

Roche Diagnostics, UCB Biopharma, Evotec International GmbH, AstraZeneca, Travere Therapeutics
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkersCKDCKD non-dialysisESKDkidney failuremortalitymortality riskprogressionprogression of renal failuresurvival analysis

Identifiers

PMID40540429
PMCPMC12677819

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.